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Abstract
Background: Glutathione S-transferase (GSTs) plays an important role in the detoxification of
many xenobiotics involved in the etiology of cancer. In different ethnic groups, variations in null
allele frequency have been observed. We have investigated GSTM1 gene polymorphisms in healthy
subjects and lung cancer patients in the Turkish population and reviewed the control subjects of
the studies performed in the Turkish population.
Methods: Following blood sampling from patients and controls, DNA samples were extracted
from the whole blood and were amplified by using polymerase chain reaction (PCR) method in all
of the 256 cases, consisting of 102 previously diagnosed with lung cancer and 154 healthy controls.
Results: The prevalence of GSTM1-null genotype in the lung cancer patients was 49%, compared
to 52.6% in the control group (OR = 1.39, 95% CI = 0.70–1.90, p = 0.57). There were also no
significant relationships in GSTM1 genotypes among histopathologic types of lung cancers (p >
0.05). The frequency of GSTM1 was found to be 41.2% (n = 1809) when the control subjects of
the studies performed in Turkish population were reviewed.
Conclusion: We have observed that GSTM1 genotype is not an independent risk factor for lung
cancer.
1. Background
Carcinoma of the lung is the most common cancer and
the most frequent cause of death in the patients with can-
cer around the world [1]. Environmental carcinogens such
as active and passive smoking, air pollution and environ-
mental exposures have strong influences on individual
factors [2]. In humans, there are several genetic polymor-
phisms of the enzymes involved in metabolic activation
and detoxification of pulmonary carcinogens including
polycyclic aromatic hydrocarbons (PAH) and aromatic
amines. Interindividual differences in ability to activate
and detoxify carcinogens are expected to affect the risk of
developing lung cancer [3]. Polymorphisms of the genes
encoding phase I and phase II xenobiotic metabolizing
Published: 26 September 2007
Journal of Carcinogenesis 2007, 6:13 doi:10.1186/1477-3163-6-13
Received: 27 June 2007
Accepted: 26 September 2007
This article is available from: http://www.carcinogenesis.com/content/6/1/13
© 2007 Demir et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Carcinogenesis 2007, 6:13 http://www.carcinogenesis.com/content/6/1/13
Page 2 of 6
(page number not for citation purposes)
enzymes have been shown to be associated with suscepti-
bility to lung cancer in a number of epidemiologic studies
[4]. However, most of these studies are limited by lack of
adequate statistical power. To overcome this limitation,
the International Collaborative Study on Genetic Suscep-
tibility to Environmental Carcinogens (GSEC) has begun
and is on-going to pool raw data of studies on metabolic
genetic polymorphisms and cancer risk [5].
Glutathione S-transferase (GSTs) plays an important role
in cellular defense mechanism since they are involved in
detoxification of many carcinogens and environmental
pollutants and facilitate their excretion and also have a
role in protection against oxidative stress [6,7]. The fre-
quencies of polymorphic genes in control populations
have been reported to be different in various ethnic
groups. In addition, interethnic differences have been
established [7-9]. GSTM1 deletion frequencies range from
42% to 60% in Caucasians [8].
Some studies suggest that the GSTM1 null genotype con-
fers an increased risk of lung cancer but this result has not
been approved by others, especially recent meta and
pooled analysis [5,7,10-13].
The aims of the present study are to evaluate the frequen-
cies of GSTM1 gene polymorphisms in Turkish popula-
tion and whether genetic polymorphisms in GSTM1
influence individual susceptibility to lung cancer in Turk-
ish population or not.
2. Methods
2.1. Study subjects and sample collection
A total 256 subjects, composed of 102 lung cancer
patients, who were admitted to Yedikule Teaching Hospi-
tal for Chest Diseases and Thoracic Surgery in Istanbul
between 2001–2005, and 154 healthy controls were
included in this study. All cancer patients and controls
were born in Turkey. The control group had neither can-
cers nor chronic diseases. The mean ages were found to be
56.3 ± 10 (range 30–75) and 35.1 ± 11 (range 20–65) in
cancer group and healthy controls, respectively. Ninety-
four patients in cancer group and 110 subjects in healthy
controls were smokers. This study was approved by local
hospital ethics committee on human research. All patients
gave informed consent.
2.2. GSTM1 genotyping
DNA samples were amplified with the primers: 5'-
GAACTCCCTGAAAAGCTAAAGC -3' and 5'-GTTGGGCT-
CAAATATACGGTGG-3' for GSTM1 which produced a 219
bp product [14]. The PCR amplification was carried out 1
µg DNA in 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 3 mM
MgCl2, 0,3 mM deoxyribonucleotide triphosphates (Fer-
mentas), 0,2 µM of each primer and 1,5 U of Taq polymer-
ase (Fermentas) in a total volume of 50 µl. Amplification
was performed with initial denaturation at 94°C for 5
minutes, followed by 30 cycles at 94°C for 1 minute,
61°C for 1 minute, and 72°C for 1 minute, and a final
extension at 72°C for 10 minute, using a MJ Research
PTC160 thermal cycler. The amplification product (10 µl)
was visualized in an ethidium bromide stained 1.5% aga-
rose gel. All the genotype determination were carried out
twice in independent experiments and all the inconclusive
samples were reanalyzed. The results are shown in figure
1.
2.3. Statistical analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences Program (SPSS, Version
10). Pearson's X2 test was used to examinutee differences
with regard to demographic variables, smoking and distri-
bution of genotypes. Associations between the GSTM1
polymorphisms and risk of lung cancer were estimated
using odds ratios (ORs) and 95% confidence intervals
(95% CIs) calculated by conditional logistic regression.
3. Results
The demographic characteristics of the cancer group and
healthy controls are shown in the Table 1. The prevalence
of GSTM1 (0/0) genotype in the cancer group was 49%
compared to 52.6% in control group. But the difference
was not statistically significant (OR = 1.39, 95% CI =
0.70–1.90, P = 0.55) (Table 2).
Histopathological evaluation, performed according to
WHO criteria, revealed that epidermoid carcinoma, aden-
ocarcinoma and the others types were present in 62.7% (n
= 64), 24.5%(n = 25) and 12.7% (n = 13) out of 102 can-
cer group, respectively. There was no statistically signifi-
cant difference among the histopathologic types of lung
cancer (p > 0.05) and prevalence of GSTM1 polymor-
phism.
4. Discussion
There are a lot of epidemiological and genetical studies
with the expectation to monitorize the risk of lung cancer
using specific biomarkers. GST gene polymorphism is one
of the subject of matter. A number of studies have been
GSTM1 genotyping Figure 1
GSTM1 genotyping. (-): water; 1, 2 : GSTM1 null genotype (0/
0); 3, 4, 5 and 6 GSTM1 +/+ or +/- genotype. M: 100 bp lad-
der size marker.Journal of Carcinogenesis 2007, 6:13 http://www.carcinogenesis.com/content/6/1/13
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tried to establish the relationship between polymorphic
expression of different GSTs and lung cancer risk in differ-
ent ethnic populations [7,10,15,16], and the results have
been conflicting [15,17]. One reason for the discrepancies
could be the fact that most studies were conducted in dif-
ferent populations (one of the discrepancies that we
encountered is due to holding the study in different pop-
ulations). However, none of the main characteristics of
the subjects explain satisfactorily the apparent discrepan-
cies (i.e. race, histological type and level of smoking). Dif-
ferent histological subtypes of lung cancer, in particular
may also be related to respective exposures or factors, and
thus need to be analyzed separately [15,18].
The M1 variant of GST (GSTM1) detoxifies reactive inter-
mediates of PAHs and other carcinogens. Although, the
relationship between GSTM 1 polymorphism and lung
cancer has been studied by various investigators, the effect
of GSTM 0/0 null allele has not been explained clearly yet.
A significant association of GSTM1 null genotype with
lung cancer has already been observed in two large studies
belongs to Japanese [19,20] and two in Chinese [21,22].
Furthermore, a study in Caucasians reported a significant
association between lung adenocarcinoma and the
GSTM1 null genotype [23]. In a meta-analysis study by
Mc. Williams et al., it was shown that GSTM 0/0 null allele
was a risk factor for the development of the lung cancer
[24]. A meta-analysis of 11 studies found an OR of 1.6
(95% CI = 1.26–2.04) for an association between the
GSTM1-null genotype and lung cancer risk [25]. A meta-
analysis published by Simone Benhamou and co-workers
reported that there was no statistically significant relation-
ship between carrying GSTM null genotype and suscepti-
bility to lung cancer but the number of the patients
carrying this genotype was higher in the lung cancer group
[12]. Although Pinarbasi et al. [26] reported a correlation
between GTSM1 and lung cancer (p = 0.0001) in the Turk-
ish population, the other trials conducted by Aras et al.
[27] and Ozturk et al. [28] in Turkish population revealed
the contrary (p > 0.05) (Table 4). In our study, we found
no statistically significant relation between GSTM null
genotype and susceptibility to lung cancer. Additionally,
the rate of GSTM null genotype was higher in control
group than cancer patients.
The frequencies of polymorphic genes in control popula-
tions have been reported to be different in various ethnic
groups. In addition, intra-ethnic differences have been
established [8,9]. GSTM1 frequencies range from 42 to
60% in Caucasians [8]. GSTM1 null genotype has been
shown to be 31 to 66% in Asians, Indians and Caucasians
[28-30]. On the other hand, GSTM1 deletion polymor-
phism for African-Americans was found to be 23–35%
[31] and for Chileans was 21% [10]. In these series the fre-
quency of GSTM1 null genotype was 52,6% which was
similar to some European countries (Germany, Denmark,
and France), Canada, and Korea (Table 4).
When the control groups of studies performed in Turkish
population are reviewed, the frequency of GSTM1 null
genotype was found to be 41.2% (n = 1809). This figure is
lower than European countries, United States, Saudi Ara-
bia, Japan, Singapore, and Korea (Table 4).
Several studies have also been carried out in this regard in
Turkish populations. However, some need verification
and others are contradictory. GSTM1 null genotype has
been shown to be 18 to 66% in Turkish population (n =
1809) (Table 3). In Ozturk and co-workers study [28],
GSTM1 null genotype incidence was found to be 49.2% in
Turkish population. While Aktas et al. [27] found the
prevalence of null polymorphism 34.7%; Pinarbasý et al.
[26] detected it to be 18% in Turkish population. The rea-
son for this difference between both studies was attributed
to regional variation of the controls included in these
Table 2: Frequency of GSTM1 genotypes in lung cancer patients and controls
Genotypes Patients n (%) Control n (%) OR(95%) CI p value
GSTT1
Present 52(51%) 73(47.4%) 1.0
Null 50(49%) 81(52.6%) 1.39(0.70–1.90) 0.57
Abbreviations: OR, odds ratio; CI, confidence interval
Table 1: Demographic characteristics of the lung cancer patients 
and controls
Characteristics Patients (n = 102) Controls (n = 154)
Mean 56.3 ± 10 35.1 ± 11
Range (30–75) (20–65)
Male 91 98
Female 11 56
Smokers 94 110
Non-smokers 8 44
Cigarettes (Package/year) 39.2 ± 4.2 14.5 ± 3.2
Histopathology
Epidermoid 
carcinoma
64(62.7%)
Adenocarcinoma 25(24.5%)
Others 13(12.7%)Journal of Carcinogenesis 2007, 6:13 http://www.carcinogenesis.com/content/6/1/13
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studies by Pýnarbas ¸ı. While Pýnarbas ¸ı included only indi-
viduals from Central Anatolia region of Turkey, Aktas did
not report such a restriction [26]. In the current series the
frequency of GSTM1 genotype was found to be 52.6% and
is the highest among the series in Turkish population
except series of Aras. The possible explanation for the high
rates of the current series and Aras' series could be the
inclusion of subject living in two large cities of Turkey,
Istanbul and Ankara containing people from all over the
country. In our previous study, there was no significant
relationship between lung cancer and gene polymor-
phism and we had concluded that insignificancy was due
to subject number inadequacy [7] but as we have involved
more subjects, we could not improve the significance.
In conclusion, we observed that carrying the GSTM1 gen-
otype is not a risk factor for lung cancer, alone. The fre-
quencies of GSTM1-null genotype in control Turkish
populations have been observed to be intra-ethnic differ-
ences. In future, the risk of lung cancer is expected to be
monitorized using specific biomarkers in genetic
researches.
Table 4: The frequency of GSTM1 null genotype in control populations, geographic distribution
Studies (year) Country Genotypes Healthy controls (n =) Percentage
Garte et al. (2001) Denmark GSTM1 null 537 53.6%
Garte et al. (2001) Finland GSTM1 null 482 46.9%
Garte et al. (2001) France GSTM1 null 1184 53.4%
Garte et al. (2001) Germany GSTM1 null 734 51.6%
Garte et al. (2001) Italy GSTM1 null 810 49.4%
Garte et al. (2001) Spain GSTM1 null 192 49.4%
Garte et al. (2001) Sweden GSTM1 null 544 55.9%
Garte et al. (2001) United Kingdom GSTM1 null 1112 57.8%
Garte et al. (2001) Netherlands GSTM1 null 419 50.4%
Garte et al. (2001) Norway GSTM1 null 423 50.6%
Garte et al. (2001) Portugal GSTM1 null 501 58.3%
Garte et al. (2001) United States GSTM1 null 1751 54.3%
Garte et al. (2001) Saudi Arabia GSTM1 null 895 56.3%
Garte et al. (2001) Canada GSTM1 null 304 51.3%
Garte et al. (2001) Singapore GSTM1 null 244 56.2%
Garte et al. (2001) Korea GSTM1 null 165 52.1%
Studies of Turkey (see Table 3) Turkey GSTM1 null 1809 41.2%
Table 3: The frequency of GSTM1 null genotype in Turkish population
Studies of Turkey Genotypes Patients (n =) Percentage Healthy Controls (n =) Percentage OR(95%) CI p value
Pýnarbas ¸ı et al (2003) (26)* GSTM1 null 101 48% 206 18% 4.14(2.36–7.27) p = 0.0001
Aras et all. (ANK) (27)* GSTM1 null 54 72.7 100 66% 0.73(0.33–1.59) p > 0.05
Öztürk et al. (2003) (28)* GSTM1 null 55 47.3% 65 49.2% p > 0.05
Curent series* GSTM1 null 102 49% 154 52.6% 1.397(0.70–1.90) p = 0.57
Ada et al. (2004) (9) GSTM1 null - - 133 51.9% - -
Özbek et al. (2001)(32) GSTM1 null - - 130 47% - -
Seyitoğlu et al. (2003) (33) GSTM1 null - - 200 47% - -
Aktas et al. (2001) (34) GSTM1 null - - 172 34.7% - -
Toruner et al. (2001) (35) GSTM1 null - - 121 45.5% - -
Tamer et al. (2004) (36) GSTM1 null - - 103 40.8% - -
Tursen et al. (2004) (37) GSTM1 null - - 178 24.2% - -
Tamer et al. (2004) (38) GSTM1 null - - 247 41.7% - -
Studies of Turkey(Total) GSTM1 null -- 1809 41.2% --
* Studies with lung cancer patientsJournal of Carcinogenesis 2007, 6:13 http://www.carcinogenesis.com/content/6/1/13
Page 5 of 6
(page number not for citation purposes)
Competing interests
The author(s) declare that they have no competing inter-
ests.
References
1. National Cancer Institute: SEER Cancer Statistics Review.
Bethesda, MD: National Institutes of Health; 2001:1973-1998. 
2. Perera FP: Molecular epidemiology of environmental carcino-
genesis.  Recent Results Cancer Res 1998, 154:39-46.
3. Raunio H, Husgafvel-Pursiainen K, Anttila S, Hietanen E, Hirvonen A,
Pelkonen O: Diagnosis of polymorphisms in carcinogen-acti-
vating and inactivating enzymes and cancer susceptibility.
Gene 1995, 159:113-21.
4. Strogn LC, Amos CI: Inherited susceptibility.  In Cancer Epidemiol-
ogy and Prevention Edited by: Schottenfeld D, Searle JG, Fraumeni JF.
Oxford University Press, NewYork; 1996:559-582. 
5. Taioli E, Gaspari L, Benhamou S, Boffetta P, Brockmoller J, Butkiewicz
D, Cascorbi I, Clapper ML, Dolzan V, Haugen A, Hirvonen A, Hus-
gafvel-Pursiainen K, Kalina I, Kremers P, Le Marchand L, London S,
Rannug A, Romkes M, Schoket B, Seidegard J, Strange RC, Stucker I,
To-Figueras J, Garte S: Polymorphisms in CYP1A1, GSTM1,
GSTT1 and lung cancer below the age of 45 years.  Int J Epide-
miol 2003, 32:60-3.
6. Hayes JD, Pulford DJ: The glutathione S-transferase supergene
family: regulation of GST and the contribution of the isoen-
zymes to cancer chemoprotection and drug resistance.  Crit
Rev Biochem Mol Biol 1995, 30:445-600.
7. Demir A, Demir I, Altýn S, Koksal V, Cetincelik U, Dincer Sİ:
GSTM1 Gene Polymorphisms on Lung Cancer Development
in the Turkish Population.  Turkish Respiratory Journal 2005,
6(1):131-134.
8. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup
JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C,
Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly
A, Dell'Omo M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein DW,
Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I,
Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L,
Lechner MC, van Lieshout EMM, London S, Manni JJ, Maugard CM,
Morita S, Nazar-Stewart V, Noda K, Oda Y, Parl FF, Pastorelli R, Pers-
son I, Peters WHM, Rannug A, Rebbeck T, Risch A, Roelandt L, Rom-
kes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim
E, Sinnet D, Strange RC, Stiicker I, Sugimura H, To-Figueras J, Vineis
P, Yu MC, Taioli E: Metabolic gene polymorphism frequencies
in control populations.  Cancer Epidemiol Biomarkers Prev 2001,
10(12):1239-1248.
9. Ada AO, Suzen SH, Iscan M: Polymorphisms of cytochrome
P450 1A1, glutathione S-transferases M1 and T1 in a Turkish
population.  Toxicol Lett 2004, 151:311-5.
10. Quinones L, Berthou F, Varela N, Simon B, Gill L, Lucas D: Ethnic
susceptibility to lung cancer : differences in CYP2E1,
CYP1A1 and GSTM1 genetic polymorphisms between
French Caucasians and Chilean populations.  Cancer Lett 1999,
141:167-71.
11. Houlston RS: Glutathione S-transferase M1 status and lung
cancer risk: a meta-analysis.  Cancer Epidemiol Biomarkers Prev
1999, 8:675-82.
12. Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butk-
iewicz D, Brockmoller J, Clapper ML, Daly A, Dolzan V, Ford J,
Gaspari L, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Ingelman-
Sundberg M, Kalina I, Kihara M, Kremers P, Le Marchand L, London
SJ, Nazar-Stewart V, Onon-Kihara M, Rannug A, Romkes M, Ryberg
D, Seidegard J, Shields P, Strange RC, Stucker I, To-Figueras J, Brennan
P, Taioli E: Meta- and pooled analyses of the effects of glutath-
ione S-transferase M1 polymorphisms and smoking on lung
cancer risk.  Carcinogenesis 2002, 23:1343-50.
13. Hung RJ, Boffetta P, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper
ML, Garte S, Haugen A, Hirvonen A, Anttila S, Kalina I, Le Marchand
L, London SJ, Rannug A, Romkes M, Salagovic J, Schoket B, Gaspari L,
Taioli E: CYP1A1 and GSTM1 genetic polymorphisms and
lung cancer risk in Caucasian non-smokers: a pooled analy-
sis.  Carcinogenesis 2003, 24:875-82.
14. Teixeira JP, Gaspar J, Martinho G, Silva S, Rodrigues S, Mayan O, Mar-
tin E, Farmer PB, Rueff J: Aromatic DNA adduct levels in coke
oven workers: correlation with polymorphisms in genes
GSTP1, GSTM1, GSTT1 and CYP1A1.  Mutat Res 2002,
517:147-55.
15. Wang J, Deng Y, Cheng J, Ding J, Tokudome S: GST genetic poly-
morphisms and lung adenocarcinoma susceptibility in a Chi-
nese population.  Cancer Lett 2003, 201:185-93.
16. Jourenkova-Mironova N, Wikman H, Bouchardy C, Voho A, Dayer P,
Benhamou S, Hirvonen A: Role of glutathione S-transferase
GSTM1, GSTM3, GSTP1 and GSTT1 genotypes in modulat-
ing susceptibility to smoking-related lung cancer.  Pharmacoge-
netics 1998, 8:495-502.
17. Hayes JD, Strange RC: Glutathione S-transferase polymor-
phisms and their biological consequences.  Pharmacology 2000,
61:154-66.
18. Le Marchand L, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR,
Lau AF: Associations of CYP1A1, GSTM1, and CYP2E1 poly-
morphisms with lung cancer suggest cell type specificities to
tobacco carcinogens.  Cancer Res 1998, 58:4858-63.
19. Hayashi S, Watanabe J, Kawajiri K: High susceptibility to lung can-
cer analyzed in terms of combined genotypes of P450IA1
and Mu-class glutathione S-transferase genes.  Jpn J Cancer Res
1992, 83(8):866-870.
20. Kihara M, Noda K, Kihara M: Distribution of GSTM1 null geno-
type in relation to gender, age and smoking status in Japa-
nese lung cancer patients.  Pharmacogenetics 1995, 5
Spec:S74-S79.
21. Lan Q, He X, Costa DJ, Tian L, Rothman N, Hu G, Mumford JL:
Indoor coal combustion emissions, GSTM1 and GSTT1 gen-
otypes, and lung cancer risk: a case-control study in Xuan
Wei, China.  Cancer Epidemiol Biomarkers Prev 2000, 9:605-8.
22. Sun GF, Shimojo N, Pi JB, Lee S, Kumagai Y: Gene deficiency of glu-
tathione S-transferase mu isoform associated with suscepti-
bility to lung cancer in a Chinese population.  Cancer Lett 1997,
113:169-72.
23. Woodson K, Stewart C, Barrett M, Bhat NK, Virtamo J, Taylor PR,
Albanes D: Effect of vitaminute intervention on the relation-
ship between GSTM1, smoking, and lung cancer risk among
male smokers.  Cancer Epidemiol Biomarkers Prev 1999, 8:965-70.
24. McWilliams JE, Sanderson BJ, Harris EL, Richert-Boe KE, Henner
WD: Glutathione S-transferase M1 deficiency and lung can-
cer risk.  Cancer Epidemiol Biomarkers Prevent 1995, 4(6):589-594.
25. Errico A, Taioli E, Chen X, Vineis P: Genetic metabolic polymor-
phisms and the risk of cancer: a review of the literature.
Biomarkers 1996, 1:149-73.
26. Pinarbasi H, Silig Y, Cetinkaya O, Seyfikli Z, Pinarbasi E: Strong asso-
ciation between the GSTM1-null genotype and lung cancer
in a Turkish population.  Cancer Genet Cytogenet 2003,
146(2):125-129.
27. Aras S: An Investigation on the frequency of GSTM1 gene in
Turkish population by RFLP: A Correlation between null
allele gene frequency and lung cancer.  Ankara Universitesi Tez
2001, 1:1-14.
28. Ozturk O, Isbir T, Yaylim I, Kocaturk CI, Gurses A: GSTM1 and
CYP1A1 gene polymorphism and daily fruit consumption in
Turkish patients with non-small cell lung carcinomas.  In Vivo
2003, 17:625-32.
29. Hong YS, Chang JH, Kwon OJ, Ham YA, Choi JH: Polymorphism of
the CYP1A1 and glutathione-S-transferase gene in Korean
lung cancer patients.  Exp Mol Med 1998, 30:192-8.
30. Persson I, Johansson I, Lou YC, Yue QY, Duan LS, Bertilsson L, Ingel-
man-Sundberg M: Genetic polymorphism of xenobiotic metab-
olizing enzymes among Chinese lung cancer patients.  Int J
Cancer 1999, 81(3):325-329.
31. Kelsey TK, Spitz MR, Zheng-Fa Z, Wiencke JK: Polymorphisms in
the glutathione S-transferase class mu and theta genes inter-
act and increase susceptibility to lung cancer in minuteority
populations (Texas, United States).  Cancer Causes Control 1997,
8:554-9.
32. Ozbek U, Aydýn M, Hatýrnaz O: Metabolizing Enzyme Polymor-
phisms (GSTM1, GSTT1, CYP1A1, CYP2D6) and Their
Association as a Potential Susceptibility to Pediatric ALL.
American Society of Hematology 43rd Annual Meeting and Exposition
Orlondo, December 7–11, FL 2001.
33. Seyitoglu A, Hatýrnaz O, Ozbek U: Detoksifikasyon Enzim Gen
Polimorfizmlerinin Akut Lösemi Etiyolojisindeki Rolleri.
Turkish Society of Hematology 30th Annual Meeting, October 10–14,
2003, ISTANBUL .Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Carcinogenesis 2007, 6:13 http://www.carcinogenesis.com/content/6/1/13
Page 6 of 6
(page number not for citation purposes)
34. Aktas D, Ozen H, Atsu N, Tekin A, Sozen S, Tuncbilek E: Glutath-
ione S-transferase M1 gene polymorphism in bladder cancer
patients. A marker for invasive bladder cancer?  Cancer Genet
Cytogenet 2001, 125:1-4.
35. Toruner GA, Akyerli C, Ucar A, Aki T, Atsu N, Ozen H, Tez M,
Cetinkaya M, Ozcelik T: Polymorphisms of glutathione S-trans-
ferase genes (GSTM1, GSTP1 and GSTT1) and bladder can-
cer susceptibility in the Turkish population.  Arch Toxicol 2001,
75:459-64.
36. Tamer L, Calikoglu M, Ates NA, Yildirim H, Ercan B, Saritas E, Unlu
A, Atik U: Glutathione-S-transferase gene polymorphisms
(GSTT1, GSTM1, GSTP1) as increased risk factors for
asthma.  Respirology 2004, 9:493-8.
37. Tursen U, Tamer L, Eskandari G, Kaya TI, Ates NA, Ikizoglu G, Atik
U: Glutathione S-transferase polymorphisms in patients with
Behcet's disease.  Arch Dermatol Res 2004, 296:185-7.
38. Tamer L, Ercan B, Camsari A, Yildirim H, Cicek D, Sucu N, Ates NA,
Atik U: Glutathione S-transferase gene polymorphism as a
susceptibility factor in smoking-related coronary artery dis-
ease.  Basic Res Cardiol 2004, 99:223-9.